Please assess the completion status of the following clinical trial:

Trial Title: Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be 19 years of age or older~* Hospitalized with COVID-19 and confirmed via SARS-CoV-2 RT-PCR testing~* Patient is willing and able to provide written consent and comply with all protocol requirements~* Patient agrees to storage of specimens for future testing~Exclusion Criteria:~* Female subjects with positive pregnancy test, are breastfeeding or planning to become pregnant/breastfeed during the study period~* Symptomatic illness exceeding 14 days from onset of illness at time of enrollment~* ICU admission on initial presentation at the hospital (includes patients with clinical indications for ICU admission as follows:~  1. Respiratory distress with requirement of O2 \>6 lpm to maintain O2 sat \>92%~ 2. Rapid escalation of O2 requirement/significant work of breathing~ 3. Hemodynamic instability: SBP \<90, MAP \<65~* Receipt of any blood products including pooled immunoglobulin or intravenous immunoglobulin (IVIg) in the past 30 days prior to enrolment~* Known IgA deficiency~* Presence of any contraindication to transfusion (or history of prior severe reactions to transfusion of blood products)

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anti-SARS-CoV-2 convalescent plasma (Type: EXPERIMENTAL): About 500 mL of type-specific anti-SARS-CoV-2 convalescent plasma collected by whole blood donation or standard pheresis from a volunteer who recovered from COVID-19 transfused intravenously as 2 aliquots of 250 mL
- Standard of care (Type: NO_INTERVENTION): Patients in the control group are those will only receive local standard of care as deemed appropriate by the primary attending physicians and guided by institutional pathways

Based on this trial design, predict the completion outcome and termination type (if applicable).